Nanjing Bioheng Biotech Co., Ltd.

CRISPR CAR T-Cell Therapy Clinical Update
Apr. 27, 2021

This week’s update looks at a CRISPR-edited CAR T-cell therapy in clinical development for the treatment of a range of B cell cancers.

Nanjing Bioheng Biotech Co., Ltd.

Relapsed or Refractory B cell Malignancies, (NCT04227015)
Sponsors:
Zhejiang University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT04154709)
Sponsors:
Xuzhou Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma, DLBCL, (NCT04026100)
Sponsors:
The First Affiliated Hospital of Nanjing Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine